In our new report Launch Readiness 2022, we consider how launch strategists may best navigate a fast-changing yet still commercially ripe environment for pharmaceutical launch readiness. We show how digital transformation and cutting-edge launch management software help companies track the status of launch activities and manage global launch challenges, in real-time and across both functions and countries.
It is probably reasonable enough by now to talk about the launch readiness landscape for medicines and vaccines as pre- and post-COVID. We can also say with some certainty that nothing will ever be the same again.
Pharmaceutical companies have more reasons than ever to hone their launch readiness skills. The question is whether they possess the new product launch strategies and tools to successfully commercialise their new medicines in an often volatile and always competitive global marketplace.
Access to medicines is a loaded term. In an ideal world, every patient would have unimpeded access to the best drug available. In reality, access is usually selective at best.